2023 Fabiola De Marchi, Ivana Munitic, Lea Vidatic, Eliša Papić, Valentino Rački, Jerneja Nimac, Igor Jurak, Gabriela Novotni, Boris Rogelj, Vladimira Vuletic, Rajka M Liscic, Jason R Cannon, Emanuele Buratti, Letizia Mazzini, Silva Hecimovic; Overlapping neuroimmune mechanisms and therapeutic targets in neurodegenerative disorders. Biomedicines 11 (10), 2793; https://doi.org/10.3390/biomedicines11102793
2023 Fabiola De Marchi, Toni Franjkic, Paride Schito, Tommaso Russo, Jerneja Nimac, Anna A Chami, Angelica Mele, Lea Vidatic, Jasna Kriz, Jean-Pierre Julien, Gordana Apic, Robert B Russell, Boris Rogelj, Jason R Cannon, Marco Baralle, Federica Agosta, Silva Hecimovic, Letizia Mazzini, Emanuele Buratti, Ivana Munitic; Emerging trends in the field of inflammation and proteinopathy in ALS/FTD spectrum disorder. Biomedicines 11 (6), 1599; https://doi.org/10.3390/biomedicines11061599
2023 Nikolina Mohovic, Josip Peradinovic, Andrea Markovinovic, Raffaello Cimbro, Zeljka Minic, Marin Dominovic, Hrvoje Jakovac, Jerneja Nimac, Boris Rogelj & Ivana Munitic; Neuroimmune characterization of optineurin insufficiency mouse model during ageing. Sci. Rep. 13, 11840 (2023); https://doi.org/10.1038/s41598-023-38875-3
2023 Josip Peradinovic, Nikolina Mohovic, Katarina Bulic, Andrea Markovinovic, Raffaello Cimbro and Ivana Munitic. Ageing-Induced Decline in Primary Myeloid Cell Phagocytosis Is Unaffected by Optineurin Insufficiency. Biology 2023, 12(2), 240; https://doi.org/10.3390/biology12020240
2022 Nikolina Prtenjaca, Matea Rob, Muhammad S. Alam, Andrea Markovinovic, Cristiana Stuani, Emanuele Buratti and Ivana Munitic. Optineurin Deficiency and Insufficiency Lead to Higher Microglial TDP-43 Protein Levels. Int. J. Mol. Sci. 2022, 23, 6829; https://doi.org/10.3390/ijms23126829
2021 De Marchi F, Munitic I, Amedei A, Berry JD, Feldman EL, Aronica E, Nardo G, Van Weehaeghe D, Niccolai E, Prtenjaca N, Sakowski SA, Bendotti C, Mazzini L. Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact. Neuroscience and Biobehavioral Reviews, 127, 958-978; https://doi.org/10.1016/j.neubiorev.2021.06.027
2020 Prtenjača N, Dominović M, Peradinović J, Šajn R, Markovinović A, Munitić I. Optineurin Dysfunction in Amyotrophic Lateral Sclerosis: Why So Puzzling?, Periodicum Biologorum, V121–122, No 1–2, 23–34, 2020; https://hrcak.srce.hr/ojs/index.php/periodicum_biologorum/article/view/10627
2020 Béland LC, Markovinovic A, Jakovac H, De Marchi F, Bilic E, Mazzini L, Kriz J, Munitic I. Immunity in amyotrophic lateral sclerosis: blurred lines between excessive inflammation and inefficient immune response. Brain Communications, 2, fcaa124; https://doi.org/10.1093/braincomms/fcaa124
2019 Smith AM, Buss F, Munitic, I. Editorial: The Role of Optineurin in Immunity and Immune-Mediated Diseases. Frontiers in Immunology 10, 2803; https://doi.org/10.3389/fimmu.2019.02803
2019 Ban, J, Sámano C, Mladinic M, Munitic, I. Glia in amyotrophic lateral sclerosis and spinal cord injury: common therapeutic targets. Croatian Medical Journal 60, 109-120; https://doi.org/10.3325/cmj.2019.60.109
2019 Hancevic, M, Bilic H, Sitas D, Pavlisa G, Borovecki F, Munitic I, Bilic E. Attenuation of ALS progression during pregnancy—lessons to be learned or just a coincidence? Neurological Sciences, 40:1275-1278; https://doi.org/10.1007/s10072-019-03748-z
2018 Markovinovic A, Ljutic T, Beland LC, Munitic I. Optineurin Insufficiency Disbalances Proinflammatory and Anti-inflammatory Factors by Reducing Microglial IFN-beta Responses. Neuroscience 388:139–151; https://doi.org/10.1016/j.neuroscience.2018.07.007
2017 Markovinovic A, Cimbro R, Ljutic T, Kriz J, Rogelj B and Munitic I. Optineurin in amyotrophic lateral sclerosis: Multifunctional adaptor protein at the crossroads of different neuroprotective mechanisms. Progress in Neurobiology, 154, 1-20; https://doi.org/10.1016/j.pneurobio.2017.04.005
2017 Malatesti N, Munitic I, and Jurak I. Porphyrin-based cationic amphiphilic photosensitisers as potential anticancer, antimicrobial and immunosuppressive agents. Biophysical Reviews, 9(2), 149-168; https://doi.org/10.1007/s12551-017-0257-7
2016 Pourcelot M, Zemirli N, Silva Da Costa L, Loyant R, Garcin D, Vitour D, Munitic I, Vazquez A, and Arnoult, D. The Golgi apparatus acts as a platform for TBK1 activation after viral RNA sensing. BMC Biology, 14, 69; https://doi.org/10.1186/s12915-016-0292-z
2016 Meena NP, Zhu G, Mittelstadt PR, Giardino Torchia ML, Pourcelot M, Arnoult D, Ashwell JD and Munitic I. The TBK1-binding domain of optineurin promotes type I interferon responses. FEBS Letters 590, 1498-1508; https://doi.org/10.1002/1873-3468.12176
2015 Li CC, Munitic I, Mittelstadt PR, Castro E, Ashwell JD. Suppression of dendritic cell-derived IL-12 by endogenous glucocorticoids is protective in LPS-induced sepsis. PLOS Biology, 13, e1002269; https://doi.org/10.1371/journal.pbio.1002269
2015 Giardino Torchia ML, Munitic I, Castro E, Herz J, McGavern DB, Ashwell JD*. c-IAP ubiquitin protein ligase activity is required for 4-1BB signaling and CD8 memory T-cell survival. European Journal of Immunology, 45, 2672-82; https://doi.org/10.1002/eji.201445342
2013 Munitic I, Giardino Torchia ML, Meena NP, Zhu G, Li CC, Ashwell JD*. Optineurin Insufficiency Impairs IRF3 but not NF-kB Activation in Immune Cells. Journal of Immunology, 191(12), 6231-40; https://doi.org/10.4049/jimmunol.1301696
Reactome releases
T. Franjkic, I. Munitic: Reactome release v84: https://reactome.org/about/news/194-v84-released
T. Franjkic, I. Munitic: Reactome release v88: https://reactome.org/about/news/246-v88-released-2
